Neuroprotective Effects Emerging evidence suggests BPC-157 may help protect the brain and nerves
Pratley RE, Aroda VR, Lingvay I, Ldemann J, Andreassen C, Navarria A et al (2018) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
They slow down how quickly food moves through your digestive system, which helps you feel full longer, and reduce cravings, especially for sugary, starchy and high-fat foods
Management Strategies for Gastrointestinal Adverse Events with GLP-1RA Therapy There are various strategies that can be employed to help manage or mitigate potential gastrointestinal adverse events when initiating a GLP-1RA for the treatment of overweight or obesity
It works as both a copper carrier and a GLP-1 (glucagon-like peptide-1) is a hormone the gut releases after you eat
Additionally, patients prescribed Wegovy often have obesity-related comorbidities, including type 2 diabetes, which independently increases UTI susceptibility